The International Association for the Study of Lung Cancer Names Elsevier New Publisher of the Journal of Thoracic Oncology
The International Association for the Study of Lung Cancer (IASLC), the world’s largest organization dedicated solely to the study of lung cancer, and Elsevier, a world-leading provider of scientific, technical, and medical information products and services, jointly announce Elsevier’s appointment as publisher of the IASLC’s official journal, Journal of Thoracic Oncology (JTO), beginning January 2016.
Published since 2006, the Journal of Thoracic Oncology emphasizes a multidisciplinary approach including original research (clinical trials and translational or basic research), reviews, and opinion pieces. This peer-reviewed journal is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. It has a global author base and readership comprised of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.
"The IASLC is very excited by the development of the JTO and to bring the journal to the next level through our partnership with Elsevier. Through this partnership, we are looking forward to leveraging Elsevier's technical developments and the synergy with Elsevier's portfolio of other oncology journals," said Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC.
“As the leading international lung cancer association, the IASLC is excited to expand the reach of the JTO and to ensure that medical professionals around the world have access to the cutting edge research being shared in the publication,” said Alex A. Adjei, MD, PhD, Editor-in-Chief of the JTO. “We are working closely with the Elsevier team to maximize the benefits that Elsevier can provide to authors and readers of the JTO. This will allow us to take advantage of synergies with Elsevier’s extensive catalog of leading cancer publications.”
Researchers, academic physicians, clinicians, and the libraries that serve them will have increased access to cutting-edge research through Elsevier’s sophisticated online channels, which offer readers enhanced features and expanded discoverability, while authors benefit from seamless and easy dissemination of their important work.
“We are extremely proud to have secured the opportunity to add this flagship title to our oncology journal portfolio,” commented Anne Kitson, Executive Vice President, Health and Medical Sciences at Elsevier. “We look forward to working in partnership with the IASLC and the JTO to enhance the journal’s reputation and influence, as well as expand its already impressive global communities of contributors and readers. We recognize the vital role that this publication plays in driving critical research forward and supporting the delivery of optimal patient care.”
With a significant Impact Factor of 5.282, JTO is ranked 30th out of 211 journals in Oncology and 7th out of 57 journals in Respiratory Medicine*. Managing Editor Mary Sharkey Todd will continue to provide support and guidance to the JTO and IASLC community.
*2014 Journal Citation Reports®, Thomson Reuters, 2015
About the International
Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in over 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. For more information, visit www.iaslc.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com